News

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs Transcript

Incyte Corporation (INCY) Discusses Solid Tumor Development Strategy and GI Oncology Programs October 26, 2026 2:30 PM EDTCompany ParticipantsPablo Cagnoni...

SeekingAlpha·00:49INCY▲+2.4%

Incyte Highlights Promising Early Data for ’890 and ’734 in GI Cancers

Incyte (NASDAQ:INCY) presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “’890,” and INCB161734, a KRAS G12D-targeted small molecule known as “’734.” The company said both program

Yahoo·22:02INCY▲+2.4%

Incyte Corporation (INCY) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow

2026-10-26. The following slide deck was published by Incyte Corporation in conjunction with this event.

SeekingAlpha·15:19INCY▲+2.4%

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

INCY and GMAB team up to evaluate a three-drug combination for first-line treatment of KRAS G12D-mutated metastatic colorectal cancer.

Yahoo·10:25INCY▲+2.4%

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

WILMINGTON, Del., October 26, 2026--Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

Yahoo·09:45INCY▲+2.4%

Can Incyte Stock Hit $170?

For questions about this article or underlying research, email help@trefis.com.

Yahoo·06:13INCY▲+2.4%

Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply

Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC)

Benzinga·23:07INCY▲+2.4%

Is Incyte (INCY) Cheap After A 120% Three Year Run?

Incyte has logged a strong multi year share price performance, and the question now is whether the business can back up that move with the cash flows needed to justify today’s valuation. Over the past 3 years, Incyte has returned 120.2%, which puts a lot of weight on whether the underlying cash generation truly supports that kind of share price gain. Fresh oncology trial collaborations and upcoming late stage data readouts may shape expectations for how quickly Incyte can turn its pipeline...

Yahoo·19:11INCY▲+2.4%

Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?

Incyte and Genmab A/S announced a clinical trial collaboration to test INCB161734 with petosemtamab and standard chemotherapy in first line KRAS G12D mutated metastatic colorectal cancer, with Genmab running the Phase 1/2 study and Incyte co funding and supplying its KRAS G12D inhibitor. The partnership gives Incyte deeper exposure to gastrointestinal oncology through a KRAS targeted combination approach, timed alongside fresh oncology data at the ESMO 2026 Congress that can shape...

Yahoo·

Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration

Incyte (NasdaqGS:INCY) and Genmab announced a new clinical trial collaboration targeting KRAS G12D-mutated metastatic colorectal cancer. The study will test a combination of Genmab’s bispecific antibody with Incyte’s selective KRAS G12D inhibitor in first-line treatment settings. The collaboration adds a fresh colorectal cancer program to Incyte’s pipeline that focuses on a mutation frequently found in these patients. The new KRAS G12D metastatic colorectal cancer trial is important, but it...

Yahoo·09:14INCY▲+2.4%

Incyte (INCY) Heads To ESMO With New Oncology Data, Is The Stock Still Undervalued?

Incyte (INCY) is back in focus as it prepares to present new oncology data at the European Society for Medical Oncology Congress in Madrid, covering several high-need solid tumor programs. That interest is landing on a stock that has been choppy in the short term but strong over longer periods, with Incyte’s 30 day share price return down 7.16% even as the year to date move sits at a 14.09% gain and the 3 year total shareholder return reaches 120.23%. This suggests sentiment has cooled...

Yahoo

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

COPENHAGEN, Denmark & WILMINGTON, Del., October 24, 2026--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi

Yahoo·07:01INCY▲+2.4%

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

WILMINGTON, Del. & COPENHAGEN, Denmark, October 24, 2026--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Yahoo·07:00INCY▲2.4%

Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?

INCY's Q3'26 results hinge on Jakafi's strong sales, Opzelura's growth and rising royalties, while higher operating expenses may pressure earnings.

Yahoo·08:25INCY▲+2.4%

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer and a mutant calreticulin, or mCALR, program for myeloproliferative neoplasms.

Yahoo·23:02INCY▲+2.4%

TD Cowen Names Top Biotech Stocks for Q4 Amid Market Volatility

Investing.com -- TD Cowen has identified seven biotech stocks as top picks for the fourth quarter, following a turbulent period that saw the sector retreat from August highs despite what the firm characterizes as solid underlying fundamentals.

Yahoo·09:34

Analysts Estimate Incyte (INCY) to Report a Decline in Earnings: What to Look Out for

TD Cowen Maintains Buy on Incyte, Raises Price Target to $140

TD Cowen analyst Tara Bancroft maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $138 to $140.

Benzinga·06:57INCY▲+2.4%

Incyte: Digesting The ESMO Updates In Pancreatic, Colorectal, And Ovarian Cancer

Incyte Corporation shares ESMO 2026 highlights: KRAS G12D, INCA33890 and CDK2 combos show solid tumor promise ahead of Jakafi LOE—click for more on INCY stock.

SeekingAlpha·10:40INCY▲+2.4%

Silence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNA

Merck KGaA is to buy Silence Therapeutics plc for $1.3B cash at $20/ADS (130% premium). Click for a look at SLN and see why I am downgrading it.

SeekingAlpha·13:23

Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

WILMINGTON, Del., October 18, 2026--Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Yahoo·18:05INCY▲+2.4%

2 High-Flying Stocks with Competitive Advantages and 1 We Question

Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.

Yahoo·10:19

Truist Securities Maintains Hold on Incyte, Raises Price Target to $115

Truist Securities analyst Srikripa Devarakonda maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.

Benzinga·09:30INCY▲+2.4%

HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.

Benzinga·02:36INCY▲+2.4%

What to Expect From Incyte’s Next Quarterly Earnings Report

Incyte will report its third-quarter earnings soon, with analysts forecasting a steep triple-digit plunge in its bottom line compared with the year-ago quarter.

Yahoo·06:42INCY▲+2.4%

Incyte to Report Third Quarter Financial Results

WILMINGTON, Del., October 08, 2026--3Q26 Earnings Announcement

Yahoo·08:00INCY▲+2.4%

RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.

Benzinga·06:04INCY▲+2.4%

If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 14.45%. Currently, Incyte has a market capitalization of $22.70 billion.

Benzinga·13:45INCY▲+2.4%

Stifel Maintains Buy on Incyte, Raises Price Target to $157

Stifel analyst Stephen Willey maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.

Benzinga·03:11INCY▲+2.4%

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Incyte (NASDAQ:INCY).

Yahoo·15:33INCY▲+2.4%

If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $23.82 billion.

Benzinga·14:00INCY▲+2.4%

Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128

Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.

Benzinga·04:32INCY▲+2.4%

INCY or TECH: Which Is the Better Value Stock Right Now?

INCY vs. TECH: Which Stock Is the Better Value Option?

Yahoo·10:40INCY▲+2.4%

Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup

INCY stock clears high growth momentum and technical screens with strong EPS growth, rising margins, and a constructive chart setup near a potential breakout.

ChartMill·07:41INCY▲+2.4%

JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123

JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.

Benzinga·09:36INCY▲+2.4%

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment

The U.S. Food and Drug Administration (FDA) on Friday approved Atebrioz (zilurgisertib) tablets, delivering a new once-daily oral treatment to patients suffering from fibrodysplasia ossificans progressiva (FOP). Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and Incyte Corporation (NASDAQ:INCY) announced the regulatory milestone, noting the medication helps reduce the volume of new abnormal bone formation in adults and children aged 12 and older. Read Also: Regeneron Secures FDA Approval For Ultra-Rar

Yahoo·08:38INCY2.4%

HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $150 to $152.

Benzinga·02:28INCY▲+2.4%

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Yahoo·19:00INCY▲+2.4%

INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill

The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.

Yahoo·14:43INCY▲+2.4%

Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data

Incyte has delivered a strong multi year share-price run, so the obvious follow up is whether the current valuation is still grounded in the cash the business is expected to generate. With investors weighing fresh product news against a higher starting price, the question is how much of Incyte's future cash flows are already embedded in today's quote. Over the past 3 years the stock has gained 110.9%, which puts pressure on investors to judge whether the cash flow outlook has risen enough to...

Yahoo·14:14INCY▲+2.4%

Incyte (INCY) Heads To EADV With New Skin Disease Trial Data

Incyte (NasdaqGS: INCY) plans to present new clinical data on its inflammation and autoimmunity portfolio at the upcoming EADV Congress. The presentation will spotlight updates for Opzelura, ruxolitinib cream, across immune mediated skin diseases studied in recent dermatology trials. Incyte will also feature new findings on povorcitinib, reflecting progress across multiple dermatological indications under investigation. These fresh EADV data drops on Opzelura and povorcitinib only tell part...

Yahoo·21:15INCY▲+2.4%

How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?

Incyte is gaining momentum, recently outperforming the biotech sector and keeping analysts broadly positive on the stock.

Yahoo·00:53INCY▲2.4%

Dow Jones Tech Titan Amazon Eyes Buy Point Amid Battle With Key Support Level

Dow Jones tech titan Amazon stock is battling with a key support level and approaching multiple new buy points.

Yahoo·13:26

Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says

Incyte's (INCY) colorectal cancer or CRC programs remain "risky and more long-term," RBC Capital Mar

Yahoo·11:45INCY▲+2.4%

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

WILMINGTON, Del., September 22, 2026--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio

Yahoo·08:30INCY▲+2.4%

RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target

RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.

Benzinga·05:24INCY▲+2.4%

Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3

Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October

Benzinga·04:36INCY▲+2.4%

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.

Benzinga·04:01

FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week

Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.

Yahoo·07:06INCY▲+2.4%

Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia

Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia.

Yahoo·16:00INCY▲+2.4%

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company’s pipeline has changed substantially over t

Yahoo·22:02INCY▲+2.4%

IBD Stock Of The Day Eyes Buy Points As Investors Dig Into Its Pipeline

Incyte is Friday's IBD Stock Of The Day. Shares are testing a trendline within a base. That would offer an early entry into the biotech..

Yahoo·12:52INCY▲+2.4%

Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum

INCY combines Minervini Trend Template strength, 93.53 RS, and high-growth momentum. Technical Rating 9, but watch resistance near 129.93 for breakout.

ChartMill·07:01INCY▲+2.4%

Dow Jones Futures Rise After Bullish S&P 500, Nasdaq Rebound; Moderna, AMD, SpaceX Flash Buy Signals

The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.

Yahoo·06:56

2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Yahoo·09:46

Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo·11:30

Incyte Corporation: Why Jakafi Is No Longer The Real Story Here

Incyte is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. See why INCY stock is a Buy.

SeekingAlpha·00:11INCY▲+2.4%

Incyte to Present at Upcoming Investor Conferences

WILMINGTON, Del., September 01, 2026--Incyte to Present at Upcoming Investor Conferences

Yahoo·09:00INCY▲+2.4%

Incyte (INCY) Just Moved, So What Is Drawing Attention Now?

Incyte (INCY) is back in focus following renewed attention on upcoming ESMO data for its KRAS G12D inhibitor, known as 734, which is being studied in combination with chemotherapy for pancreatic ductal adenocarcinoma. The renewed focus on Incyte comes after a strong run in the share price, with the latest close at US$124.37 and a 90 day share price return of 30.11%. That move sits within a broader trend where the year to date share price return is 22.63%, while total shareholder return over 1...

Yahoo·10:05INCY▲+2.4%